Imaging microvascular structure with contrast enhanced MRI.

Over the past 10 years there has been increasing interest in the development of novel MRI techniques that enable researchers and clinicians to study the development and structure of vasculature in pathological tissues. Although the majority of this work has been performed in studies of human tumours the techniques are potentially widely applicable in other pathological states [1–4]. All tissues depend on their vasculature for an adequate supply of nutrients and removal of waste metabolic materials. As tissues develop, an adequate and appropriately structured vascular supply must develop at the same time. This process, known as angiogenesis, is also an essential component of the behaviour of many pathological tissues including tumours and inflammatory disease [1, 5]. More importantly, the angiogenic process appears to be largely independent of the developing tissue. This has given rise to the concept of antiangiogenic therapies which could be effective in a wide range of tumours independent of the tissue type. The angiogenic process is complex and can be stimulated by any one of several mechanisms. Typically, growth of tissue which has outstripped its local blood supply results in regional hypoxia and hypoglycaemia which stimulates the release of local chemical messengers from the cells of the tissue itself. The best known of these messengers is the cytokine, vascular endothelial growth factor (VEGF) [6–9]. VEGF is a common and potent angiogenic stimulator, which is found in many pathological tissues. It is released in response to local hypoglycaemia and/or hypoxia and has several effects each of which will improve metabolic supply. In the short term VEGF will act directly on local capillaries to increase endothelial permeability resulting in an immediate increase in the supply of nutrients [10]. This increase in permeability is also believed to form an important part of the metastatic mechanism allowing passage of tumour cells into the circulation. In the medium to long term, VEGF will stimulate mitosis in endothelial cells from local blood vessels so that they divide and develop a new vascular infrastructure to supply the tumour. The angiogenic mechanism also is responsible for breakdown of local connective tissues, which allows in-growth of new blood vessels. Where the angiogenic process fails tissue development cannot occur and novel antiangiogenic therapies are currently being developed which use this mechanism for the treatment of a wide range of cancers and other pathologies [11, 12]. The increasing understanding of the role of the angiogenic process in disease progression has led to interest in methods for documenting the presence and activity of angiogenesis [12–14]. In particular there has been considerable interest in the development of reliable quantitative methods which can provide independent indicators of the status of, and changes in, microvascular structure [13, 14]. In pathological tissues the angiogenic process is often abnormal, leading to the development of distorted vascular beds characterized by an excessive proportion of blood vessels and blood vessels with abnormal morphology and flow characteristics [15]. Central areas of a rapidly growing tumour will commonly exhibit inadequate blood flow due to reduce local perfusion pressure resulting from a combination of inadequate vascularization and increased interstitial tumour pressure. Finally, the angiogenic neovasculature will exhibit increase endothelial permeability to medium and large sized molecules [16, 17]. Initial studies of microvascular structure in tumours were undertaken using histological techniques, however these are essentially unsatisfactory for a number of reasons [18, 19]. Pathological assessment relies on the acquisition of tissue samples which is clearly invasive and which can be repeated only infrequently. Furthermore, many tumours and other pathological tissues demonstrate considerable heterogeneity in microvascular structure so that isolated regional biopsies may give misleading information. These limitations have led to the development of imaging based methods for quantification of microvascular structure. These methods are commonly based on dynamic contrast enhanced imaging techniques using MRI or CT data collection combined with analytic algorithms to calculate descriptive parameters related to microvascular structure. The availability of quantitative imaging based methods to describe the microvasculature in biological tissues is potentially of considerable importance. Such methods can provide important surrogate markers of therapeutic response in trials of novel antiangiogenic therapy and the majority of applications to date have been in this area. However, these techniques can also be seen to have directly clinical relevance providing information about diagnosis, tumour grade, therapeutic response, tumour recurrence and prognosis. At the present time the majority of technical development of these techniques has been centred around the use of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). This article will describe the development and range of DCE-MRI techniques and the range of image analysis approaches available. The article aims to provide insight into the benefits and disadvantages of specific approaches rather than to detail the actual analysis mechanisms in detail.

[1]  J T Ennis,et al.  Breast disease: tissue characterization with Gd-DTPA enhancement profiles. , 1990, Radiology.

[2]  P. Tofts Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[3]  A. Jackson,et al.  Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors , 2000, Journal of magnetic resonance imaging : JMRI.

[4]  David L Buckley,et al.  Uncertainty in the analysis of tracer kinetics using dynamic contrast‐enhanced T1‐weighted MRI , 2002, Magnetic resonance in medicine.

[5]  K. Plate,et al.  Role of VEGF in developmental angiogenesis and in tumor angiogenesis in the brain. , 2004, Cancer treatment and research.

[6]  Jamal Zweit,et al.  Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. , 2002, Journal of the National Cancer Institute.

[7]  A R Padhani,et al.  Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics , 1997, Journal of magnetic resonance imaging : JMRI.

[8]  J C Waterton,et al.  Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast‐enhanced dynamic MR imaging , 2000, Journal of magnetic resonance imaging : JMRI.

[9]  A. Dzik-Jurasz The development and application of functional nuclear magnetic resonance to in vivo therapeutic anticancer research , 2004 .

[10]  A. Padhani,et al.  Reproducibility of quantitative dynamic MRI of normal human tissues , 2002, NMR in biomedicine.

[11]  B. Rosen,et al.  Susceptibility contrast imaging of cerebral blood volume: Human experience , 1991, Magnetic resonance in medicine.

[12]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.

[13]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[14]  A. Jackson,et al.  Parametric mapping of scaled fitting error in dynamic susceptibility contrast enhanced MR perfusion imaging. , 2000, The British journal of radiology.

[15]  P. Johannsen,et al.  Cerebral Blood Flow Measurements by Magnetic Resonance Imaging Bolus Tracking: Comparison with [15O]H2O Positron Emission Tomography in Humans , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[17]  D. Gadian,et al.  Delay and dispersion effects in dynamic susceptibility contrast MRI: Simulations using singular value decomposition , 2000, Magnetic resonance in medicine.

[18]  A. Jackson,et al.  Reproducibility of T2* blood volume and vascular tortuosity maps in cerebral gliomas , 2001, Journal of magnetic resonance imaging : JMRI.

[19]  Peter Reimer,et al.  Cerebral MR Perfusion Imaging: Principles and Current Applications , 2000 .

[20]  E. Paleolog,et al.  From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. , 2003, Birth defects research. Part C, Embryo today : reviews.

[21]  S. Ozalp,et al.  Microvessel density (MVD) as a prognosticator in endometrial carcinoma. , 2003, European journal of gynaecological oncology.

[22]  G P Liney,et al.  In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland , 1999, NMR in biomedicine.

[23]  A. Jackson,et al.  Abnormalities of the contrast re‐circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast‐enhanced imaging: A possible marker of vascular tortuosity , 2000, Journal of magnetic resonance imaging : JMRI.

[24]  M. Shibuya VEGF-receptor inhibitors for anti-angiogenesis. , 2003, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[25]  A. Jackson,et al.  Improving estimates of endothelial permeability surface area product using constrained fitting parameters for the estimation of the plasma tracer concentration function (PTCF) , 2000 .

[26]  N. Thacker,et al.  Breath‐hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first‐pass leakage profile model , 2002, NMR in biomedicine.

[27]  B R Rosen,et al.  Mr contrast due to intravascular magnetic susceptibility perturbations , 1995, Magnetic resonance in medicine.

[28]  Y Yonekura,et al.  Vascular permeability: quantitative measurement with double-echo dynamic MR imaging--theory and clinical application. , 2000, Radiology.

[29]  A R Padhani,et al.  Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. , 2001, Clinical radiology.

[30]  M. Décorps,et al.  Methodology of brain perfusion imaging , 2001, Journal of magnetic resonance imaging : JMRI.

[31]  Alan Jackson,et al.  New hybrid technique for accurate and reproducible quantitation of dynamic contrast‐enhanced MRI data , 2003, Magnetic resonance in medicine.

[32]  Alan Jackson,et al.  A comparison of Ktrans measurements obtained with conventional and first pass pharmacokinetic models in human gliomas , 2004, Journal of magnetic resonance imaging : JMRI.

[33]  D. Cantú de León,et al.  Significance of microvascular density (MVD) in cervical cancer recurrence. , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[34]  J. Allison,et al.  Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. , 1993, Magnetic resonance imaging.

[35]  M. Neeman,et al.  Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Mestan,et al.  Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. , 2004, Biochimica et biophysica acta.

[37]  A. Padhani,et al.  Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis , 2002, NMR in biomedicine.

[38]  Ting-Yim Lee,et al.  An Adiabatic Approximation to the Tissue Homogeneity Model for Water Exchange in the Brain: I. Theoretical Derivation , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  P. Kristjansen,et al.  Tumor angiogenesis ‐ a new therapeutic target in gliomas , 1998, Acta neurologica Scandinavica.

[40]  Bruce R. Rosen,et al.  Echo-Planar MR Cerebral Blood Volume Mapping of Gliomas , 1995 .

[41]  Alan Jackson,et al.  Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade. , 2002, AJNR. American journal of neuroradiology.